Sarepta Therapeutics (NASDAQ:SRPT) Hits New 52-Week Low – Time to Sell?

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) hit a new 52-week low during mid-day trading on Monday . The company traded as low as $96.75 and last traded at $97.53, with a volume of 357 shares traded. The stock had previously closed at $97.19.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on SRPT shares. Scotiabank initiated coverage on Sarepta Therapeutics in a research note on Friday, March 7th. They set a “sector perform” rating and a $105.00 target price for the company. Deutsche Bank Aktiengesellschaft initiated coverage on Sarepta Therapeutics in a report on Tuesday, February 11th. They issued a “hold” rating and a $136.00 price target on the stock. Needham & Company LLC restated a “buy” rating and issued a $202.00 price target on shares of Sarepta Therapeutics in a report on Tuesday. HC Wainwright restated a “sell” rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a report on Thursday, February 27th. Finally, Royal Bank of Canada lowered their price target on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $170.23.

Sarepta Therapeutics Stock Down 27.4 %

The firm has a fifty day moving average price of $110.18 and a 200-day moving average price of $119.13. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The firm has a market cap of $7.14 billion, a price-to-earnings ratio of 58.83 and a beta of 0.79.

Insider Transactions at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the firm’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the sale, the director now owns 27,812 shares in the company, valued at $2,771,187.68. This trade represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Several hedge funds have recently made changes to their positions in the business. Wealth Enhancement Advisory Services LLC raised its position in shares of Sarepta Therapeutics by 4.9% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,699 shares of the biotechnology company’s stock worth $571,000 after buying an additional 218 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of Sarepta Therapeutics in the 4th quarter worth $244,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Sarepta Therapeutics by 11.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 299,301 shares of the biotechnology company’s stock worth $36,392,000 after buying an additional 31,098 shares during the period. Woodline Partners LP purchased a new position in shares of Sarepta Therapeutics in the 4th quarter worth $5,713,000. Finally, Vestal Point Capital LP purchased a new position in shares of Sarepta Therapeutics in the 4th quarter worth $30,398,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.